,
, 61 6.1.5. Inhibiteurs de la dopa-décarboxylase périphérique (IDDP)
, PARTIE 2 : L'apport de l'imagerie moléculaire appliquée à la thérapie de la maladie de Parkinson, p.69
Exposition de résultats d'analyses préliminaires réalisées par MALDI, vol.26 ,
, 79 8.1. Analyse de coupes cérébrales murines témoin et test, Analyse quantitative comparative de phospholipides sur des coupes encéphaliques murines
, Application de l'imagerie moléculaire à la maladie de Parkinson
Member of the Royal College of Surgeons. An Essay on the Shaking Palsy ,
Place de la L-dopa dans la maladie de Parkinson en, La Lettre du Neurologue, vol.15, p.2, 2011. ,
Experimental-pharmacological and clinical studies on a new spasmolytic "Spadon, Wien Klin Wochenschr, vol.75, pp.189-92, 1963. ,
Modification of parkinsonism-chronic treatment with L-DOPA, The New England Journal of Medicine, vol.280, pp.337-382, 1969. ,
?-Synuclein in Lewy bodies, Nature, vol.388, pp.839-840, 1997. ,
2013) ?-synuclein elevation in human neurodegenerative diseases: Experimental, pathogenetic, and therapeutic implications, Mol. Neurobiol, vol.47, pp.484-494 ,
The ?-Synucleinopathies : Parkinson's, 2000. ,
Dementia with Lewy Bodies, and Multiple System Atrophy, Ann. N.Y. Acad. Sci, vol.920, pp.16-27 ,
Mitochondrial-membrane association of ?synuclein: Pros and cons in consequence of Parkinson's disease pathophysiology, Gene Reports, vol.16, p.100423, 2019. ,
?-synuclein in Lewy bodies, Nature, vol.388, pp.839-840, 1997. ,
Mitochondrial-membrane association of ?-synuclein: Pros and cons in consequence of Parkinson's disease pathophysiology, Gene Reports, vol.16, p.100423, 2019. ,
Marleen van Rossum, Daniella Goldfarb & Philipp Selenko. Structural disorder of monomeric ?-synuclein persists in mammalian cells, Nature, vol.530, pp.45-50, 2016. ,
Single-molecule FRET detection of early-stage conformations in ?-synuclein aggregation, Methods in Molecular Biology, pp.221-233, 1948. ,
Multitude NMR studies of ?-synuclein familial mutants: probing their differential aggregation propensities, Chem Commun (Camb), vol.54, issue.29, pp.3605-3608, 2018. ,
Preparation and Characterization of Stable ?-Synuclein Lipoprotein Particles ,
, J Biol Chem, vol.291, issue.16, pp.8516-8543, 2016.
Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system, Neuron, vol.25, issue.1, pp.239-52, 2000. ,
Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis, Neuron, vol.65, issue.1, pp.66-79, 2010. ,
?-synuclein promotes snare-complex assembly in vivo and in vitro, Science, vol.329, pp.1663-1667, 2010. ,
Human ?-synuclein modulates vesicle trafficking through its interaction with prenylated rab acceptor protein 1, Biochem. Biophys. Res. Commun, vol.412, pp.526-531, 2011. ,
Increased expression of ?-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis, Neuron, vol.65, pp.66-79, 2010. ,
Regulation of exocytosis and mitochondrial relocalization by Alpha-synuclein in a mammalian cell model, Npj Parkinson's Disease, vol.5, p.12, 2019. ,
Alphasynuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae, Mol Biol Cell, vol.19, issue.3, pp.1093-103, 2008. ,
Native ?-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife, vol.2, p.592, 2013. ,
Stabilization of alphasynuclein secondary structure upon binding to synthetic membranes, J Biol Chem ,
, Apr, vol.17, issue.16, pp.9443-9452
Alpha-Synuclein membrane interactions and lipid specificity, J Biol Chem, vol.275, issue.44, pp.34328-34362, 2000. ,
?-Synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies, Mol. Cell. Proteomics, vol.12, pp.3543-3558, 2013. ,
Structural Insights into ?-Synuclein Fibril Polymorphism: Effects of Parkinson's Disease-Related C-Terminal Truncations, Journal of Molecular Biology, vol.431, issue.19, pp.3913-3919, 2019. ,
Alphasynuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma, Faseb J, vol.17, pp.1945-1952, 2003. ,
Are synucleinopathies prion-like disorders?, Lancet Neurology, vol.9, pp.1128-1166, 2010. ,
Dissecting the potential molecular mechanisms underlying ?synuclein cell-to-cell transfer in Parkinson's disease, Parkinsonism Relat Disord, vol.15, issue.3, pp.143-147, 2009. ,
Prion-like mechanisms in neurodegenerative diseases, Nat Rev Neurosci, vol.11, pp.155-159, 2010. ,
Is Parkinson's disease a prion disorder?, Proc Natl Acad Sci, vol.106, pp.12571-12572, 2009. ,
Les synucléinopathies sont-elles des maladies à prions ? Pratique neurologique -FMC, vol.9, pp.145-151, 2018. ,
?-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis, Proteins and Proteomics, vol.1867, issue.10, pp.890-908, 2019. ,
Structural and functional characterization of two alpha-synuclein strains, Nature Communications, vol.4, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01183047
Unlike Twins: An NMR Comparison of Two ?synuclein Polymorphs Featuring Different Toxicity, PloS One, vol.9, p.90659, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01181195
La démence à corps de Lewy, La Revue de Gériatrie, vol.25, pp.493-498, 2000. ,
The difference in putamen volume between MSA and PD: Evidence from a meta-analysis. Parkinsonism and Related Disorders, vol.20, pp.873-877, 2014. ,
Accelerated in vitro fibril formation by a mutant ?-synuclein linked to early-onset Parkinson disease, Nat. Med, vol.4, pp.1318-1320, 1998. ,
Genome-wide association study reveals genetic risk underlying Parkinson's disease, Nat. Genet, vol.41, pp.1308-1312, 2009. ,
Alphasynuclein mRNA expression in sporadic Parkinson's disease, Mov. Disord, vol.20, issue.5, pp.620-623, 2005. ,
Oxidative stress induces amyloid-like aggregate formation of nacp/?-synuclein in vitro, Neuroreport, vol.10, pp.717-721, 1999. ,
Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins, J. Biol. Chem, vol.276, pp.41958-41962, 2001. ,
The formation of highly soluble oligomers of ?-synuclein is regulated by fatty acids and enhanced in Parkinson's disease, Neuron, vol.37, pp.583-595, 2003. ,
?-synuclein membrane interactions and lipid specificity, J. Biol. Chem, vol.275, pp.34328-34334, 2000. ,
Neurodegenerative disease: Amyloid pores from pathogenic mutations, Nature, vol.418, p.291, 2002. ,
The aggregation and fibrillation of ?-synuclein, Acc. Chem. Res, vol.39, pp.628-634, 2006. ,
Vesicle permeabilization by protofibrillar ?-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism, Biochemistry, vol.41, pp.4595-4602, 2002. ,
Metabolic Investigations of the Molecular Mechanisms Associated with Parkinson's Disease, vol.7, p.22, 2017. ,
The role of environmental toxins in the etiology of Parkinson's disease, Trends NeuroSci, vol.12, pp.49-54, 1989. ,
Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration, Neurotoxicology, vol.32, pp.586-595, 2011. ,
Paraquat is excluded by the blood brain barrier in rhesus macaque: An in vivo pet study, Brain Res, vol.1259, pp.74-79, 2009. ,
Blood-brain barrier breakdown in the aging human hippocampus, Neuron, vol.85, pp.296-302, 2015. ,
, The prevalence of Parkinson's disease: A systematic review and meta-analysis
, Movement Disorders, vol.29, issue.13, pp.1583-1590
,
, Données nationales et régionales 2010-2015, 2018.
Gender differences in Parkinson's disease, J Neurol Neurosurg Psychiatry, vol.78, pp.819-824, 2007. ,
Agricultural activities and the incidence of Parkinson's disease in the general French population, Eur J Epidemiol, vol.32, issue.3, pp.203-216, 2017. ,
Farming and incidence of motor neuron disease: French nationwide study, Eur J Neurol, vol.24, issue.9, pp.1191-1196, 2017. ,
Prévalence de la maladie de Parkinson et coût pour l'Assurance maladie en 2000 en France métropolitaine. Revue Médicale de l'Assurance Maladie, vol.36, pp.113-135, 2005. ,
,
, Parkinson's disease incidence and prevalence assessment in France using the national healthcare insurance database, Eur J Neurol, vol.22, issue.3, pp.464-71, 2015.
Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease, Neurology, vol.82, pp.419-445, 2014. ,
The scientific bases to consider Parkinson's disease an occupational disease in agriculture professionals exposed to pesticides in France, J Epidemiol Community Health, vol.70, issue.4, pp.319-340, 2016. ,
Persistent organochlorine pesticides in serum and risk of Parkinson disease, Neurology, vol.74, pp.1055-61, 2010. ,
CYP2D6 polymorphism, pesticides exposure, and Parkinson's disease, Ann Neurol, vol.55, pp.430-434, 2004. ,
Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson's disease, Arch Neurol, vol.67, p.739, 2010. ,
Lack of replication of the GRIN2A-by-Coffee interaction in Parkinson disease, PloS Genet, vol.10, p.1004788, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-01160040
Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee, PloS Genet, vol.7, p.1002237, 2011. ,
Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study, Neurology, vol.91, issue.22, pp.2045-2056, 2018. ,
Anatomie et physiologie humaine, 2018. ,
Troubles moteurs centraux (syndrome extrapyramidal, syndrome pyramidal) ,
Chapitre 6 : Physiopathologie : organisation des ganglions de la base, Defebvre L, Verin M. La maladie de Parkinson. 3 ème édition, pp.45-54, 2015. ,
Understanding the dopaminergic deficits in Parkinson's disease: Insights into disease heterogeneity, J Clin Neurosci, vol.16, issue.5, pp.620-625, 2009. ,
Somatotopic organization of the primate basal ganglia, Front. Neuroanat, vol.5, p.26, 2011. ,
Les maladies de Parkinson et de Huntington sont toutes deux liées à des lésions des ganglions de la base. Mais quelles sont ces structures et à quoi servent-elles ? ,
The pedunculopontine nucleus: its role in the genesis of movement disorders, Yonsei Med J, vol.41, pp.167-184, 2000. ,
,
Toward sophisticated basal ganglia neuromodulation: Review on basal ganglia deep brain stimulation, Neuroscience & Biobehavioral Reviews, vol.58, pp.186-210, 2015. ,
, What brain areas are affected by Parkinson's?, MEDIUM
Stages in the development of Parkinson's disease-related pathology, Cell Tissue Res, vol.318, issue.1, pp.121-134, 2004. ,
, Noyau tubero-mammilaire
, Le Cerveau, issue.3
Chapitre 5 : Neuropathologie, Defebvre L, Verin M. La maladie de Parkinson. 3 ème édition, pp.55-68, 2015. ,
, , vol.2, p.6, 2018.
, tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of parkinson's disease in mice, Journal of the Neurological Sciences, vol.392, pp.77-82
Prof Monique MB Breteler. Epidemiology of Parkinson's disease ,
, Lancet Neurol, vol.5, issue.6, pp.525-535, 2006.
, HAS -Service évaluation de la pertinence des soins et amélioration des pratiques et des parcours. Guide du parcours de soins -Maladie de Parkinson -Septembre, pp.978-980, 2016.
, Parkinson's disease biomarkers based on ?-synuclein. JNC, Volume150, Issue5, Special Issue: Synuclein Meeting, pp.626-636, 2019.
Smelling Parkinson's Disease: New Metabolomic Biomarker for PD, ACS Cent Sci, vol.5, issue.4, pp.575-576, 2019. ,
Accuracy of clinical diagnosis of idiopathic ,
, Parkinson's disease: a clinico-pathological study of 100 cases, J Neurol Neurosurg Psychiatry, vol.55, pp.181-184, 1992.
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study, Neurology, vol.42, pp.1142-1146, 1992. ,
Magnetic resonance imaging in parkinsonism, Clin, vol.10, pp.405-420, 1992. ,
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service, Brain, vol.125, pp.861-870, 2002. ,
The Parkinson's complex: parkinsonism is just the tip of the iceberg, Ann Neurol, vol.59, pp.591-596, 2006. ,
Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis, Neurology, vol.86, pp.566-576, 2016. ,
, Consulté le 03/05/2019). Maladie de Parkinson
Chapitre 7 : Signes moteurs ,
3 ème édition, pp.55-68, 2015. ,
Quantification of the motor symptoms of Parkinson's disease, International IEEE/EMBS Conference on Neural Engineering, vol.8008297, pp.82-85, 2017. ,
Contribution of Jules Froment to the study of Parkinsonian rigidity, pp.909-914, 2007. ,
URL : https://hal.archives-ouvertes.fr/inserm-00391547
Parkinsonisme frustre et perte des mouvements automatiques associés, sans rigidité apparente. De la rigidité latente et des moyens de la rendre évidente, Rev Neurol, vol.I, pp.658-666, 1926. ,
,
DATATOP: a multicenter clinical trial in early Parkinson's disease, Arch Neurol, vol.46, pp.1052-60, 1989. ,
Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications, Front. Neurol, 2014. ,
Dyskinesia caused by L-DOPA, Rev Neurol, 2002. ,
Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism, Movements Disorders, pp.1632-1642, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01797158
Do parkinsonian symptoms and Levodopainduced dyskinesias start in the foot, Neurology, vol.44, pp.1613-1619, 1994. ,
Clinical aspects of motor fluctuations in Parkinson's disease, Neurology, 1994. ,
Chapitre 8 : Signes non moteurs ,
La maladie de Parkinson. 3 ème Edition, pp.69-81, 2015. ,
Reward-learning and the novelty-seeking personality: A between-and within-subjects study of the effects of dopamine agonists on young Parkinson's patients, BRAIN, vol.132, pp.2385-95, 2009. ,
Pharmacologie des médicaments Antiparkinsoniens et des médicaments de la Maladie d'Alzheimer. Cours de 4 ème année de Pharmacie, matière Système Nerveux Central ,
Chapter 33 The history of movement disorders, Handbook of Clinical Neurology, vol.95, pp.501-546, 2009. ,
Les grandes avancées -La stimulation cérébrale profonde : une petite révolution ,
Maladie de Parkinson. 2 ème édition, collection Conduites, Doin, 2006. ,
, Leçons Sur Les Maladies Du Système Nerveux, pp.1872-1873
Cholinergic-anticholinergic antagonism in parkinsonism, Arch Neurol, vol.17, pp.124-136, 1967. ,
The scientific and clinical basis for the treatment of Parkinson disease, NEUROLOGY, vol.72, issue.4, pp.1-136, 2009. ,
Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches, Can J Neurol Sci, vol.11, pp.210-220, 1984. ,
Prise en charge globale et multidisciplinaire du patient parkinsonien, 2004. ,
Traitement initial de la maladie de Parkinson ,
, N° 1-C2, La Presse Médicale, vol.36, pp.86-91, 2007.
A Concise History of Mycotoxin Research, J. Agric. Food Chem, vol.65, pp.7021-7033, 2017. ,
Women pioneers in basal ganglia surgery, Parkinsonism Relat Disord, vol.20, issue.2, pp.137-141, 2014. ,
Deep brain stimulation between 1947 and 1987: the untold story, Neurosurgical Focus FOC, vol.29, issue.2, p.1, 2010. ,
Twenty-four years of deep brain stimulation of the subthalamic nucleus, Revue Neurologique, vol.173, issue.3, pp.103-105, 2017. ,
Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation, The Lancet, vol.345, pp.91-95, 1995. ,
Deep brain stimulation for Parkinson's disease: disrupting the disruption, Lancet. Neurol, vol.1, issue.4, pp.225-256, 2002. ,
Globus pallidus internus deep brain stimulation improves axial symptoms of Parkinson patients after long-term subthalamic nucleus stimulation: A case series study, Interdisciplinary Neurosurgery. Advanced Techniques and Case Management, vol.18, p.100516, 2019. ,
Deep Brain Stimulation of the Pedunculopontine Nucleus Area in Parkinson Disease: MRI-Based Anatomoclinical Correlations and Optimal Target, Clinical Neurosurgery, vol.84, issue.2, pp.506-518, 2019. ,
URL : https://hal.archives-ouvertes.fr/cea-02186436
Globus pallidus interna or subthalamic nucleus deep brain stimulation for parkinson disease a review, JAMA Neurology, vol.75, issue.3, pp.367-372, 2018. ,
An electronic device for artefact suppression in human local field potential recordings during deep brain stimulation, Journal of Neural Engineering, vol.4, issue.2, 2007. ,
Mechanisms of deep brain stimulation: excitation or inhibition, Mov. Disord, vol.17, issue.3, pp.69-72, 2002. ,
Mechanisms of action of deep brain stimulation (DBS) ,
, Neuroscience and Biobehavioral Reviews, vol.32, issue.3, pp.388-407, 2008.
Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease, The Lancet Neurology, vol.8, issue.1, pp.67-81, 2009. ,
The mechanisms of action of deep brain stimulation and ideas for the future development, Progress in Neurobiology, vol.133, pp.27-49, 2015. ,
Lead Angle Matters: Side Effects of Deep Brain Stimulation Improved with Adjustment of Lead Angle, Neuromodulation, pp.877-881, 2016. ,
Dyspnea as a side effect of subthalamic nucleus deep brain stimulation for Parkinson's disease, Respiratory Physiology and Neurobiology, vol.192, issue.1, pp.128-133, 2014. ,
Correlation among anatomic landmarks, location of subthalamic deep brain stimulation electrodes, stimulation parameters, and side effects during programming monopolar review, Operative Neurosurgery, vol.11, issue.1, pp.99-108, 2015. ,
Clinical predictive factors of subthalamic stimulation in Parkinson's disease, Brain, vol.125, issue.3, pp.575-583, 2002. ,
Interactions between deep brain stimulation and levodopa in parkinson's disease, Neurology, vol.57, issue.10, pp.1835-1842, 2001. ,
, Burn DJ the effects of deep brain stimulation and levodopa on postural sway in subjects with Parkinson's disease, Neurosurgery & Psychiatry, vol.73, p.240, 2002.
, COMMISSION NATIONALE
,
Aggregation of ?-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies, Am J Pathol, vol.152, pp.879-884, 1998. ,
,
, Identification de micro-organismes par spectrométrie de masse MALDI-TOF MS
Distribution of Lipids in the Human Brain and their Differential Expression in Alzheimer's Disease: A Matrix-Assisted Laser Desorption/Ionisation-Imaging Mass Spectrometry (MALDI-IMS) Study. Doctor of Philosophy in Anatomy, 2016. ,
, Analyseur à temps de
, , 2016.
Mécanismes fondamentaux de formation de fibres amyloïdes par la protéine a-synucléine dans la maladie de Parkinson : Modélisation quantitative, Med Sci, vol.31, issue.6-7, pp.597-600, 2015. ,
A Review of Biomarkers Use in Parkinson with Deep Brain Stimulation: A Successful Past Promising a Bright Future, World Neurosurgery, vol.123, pp.197-207, 2019. ,
Discovery of volatile biomarkers of parkinson's disease from sebum, ACS Central Science, vol.5, issue.4, pp.599-606, 2019. ,
Salivary alpha-synuclein as a biomarker for Parkinson's disease: A systematic review, Journal of Neural Transmission, 2019. ,
Phosphorylated ?synuclein deposits in sural nerve deriving from schwann cells: A biomarker for parkinson's disease. Parkinsonism and Related Disorders, vol.60, pp.57-63, 2019. ,
MALDI-TOF MS contribution to the diagnosis of campylobacter rectus multiple skull base and brain abscesses, New Microbes and New Infections, vol.19, pp.83-86, 2017. ,
Comparative proteomics analysis of human osteosarcoma by 2D DIGE with MALDI-TOF/TOF MS, Journal of Bone Oncology, vol.5, issue.4, pp.147-152, 2016. ,
Applications of HPLC-MALDI-TOF MS/MS phosphoproteomic analysis in oncological clinical diagnostics, Current. Proteomics, vol.8, issue.2, pp.153-167, 2011. ,
, , 2020.
, Long-term outcomes following deep brain stimulation for parkinson's disease, Journal of Neurosurgery, vol.132, issue.1, pp.205-210
Aspects opératoires et péri-opératoires de la stimulation cérébrale profonde, Rev Med Suisse, vol.11, pp.972-976, 2015. ,